Parameter | Final model | Bootstrap (n = 1,000) | |||
---|---|---|---|---|---|

Estimate | RSE (%) | 2.5th percentile | Median | 97.5th percentile | |

CL_{70kg} (liters/h) | 13.8 | 6.2 | 12.3 | 13.8 | 15.7 |

V_{70kg} (liters) | 63.6 | 5.0 | 59.0 | 64.1 | 71.4 |

TM_{50} (wks) | 39.5 | 12.1 | 32.5 | 39.4 | 53.4 |

HILL | 2.8 | 33.7 | 1.5 | 3.0 | 5.1 |

Albumin on V exponent | −0.83 | 27.9 | −1.29 | −0.87 | −0.43 |

Alpha-1 acid glycoprotein on V exponent | −0.25 | 44.0 | −0.41 | −0.25 | −0.03 |

IIV (CL) (%) | 58.5 | 11.5 | 52.1 | 58.4 | 64.8 |

IIV (V) (%) | 11.6 | 145.5 | 5.9 | 15.7 | 27.9 |

ρ CL-V | 0.8 | 64.5 | 0 | 0.7 | 0.8 |

Prop., PTN POPS (%) | 33.6 | 16.5 | 26.7 | 32.7 | 38.0 |

Prop., Staph Trio (%) | 32.1 | 28.8 | 19.3 | 31.1 | 40.1 |

Prop., CLIN01 (%) | 20.3 | 30.4 | 13.0 | 18.7 | 25.0 |

↵a RSE, relative standard error; CL

_{70kg}, population clearance estimate scaled to a 70-kg adult;*V*_{70kg}, population volume of distribution estimate scaled to a 70-kg adult; TM_{50}, maturation half-life calculated as a function of PMA; HILL, Hill coefficient in sigmoidal maturation function; IIV (CL), interindividual variability in drug clearance; IIV (*V*), interindividual variability in volume; PTN POPS, Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care; Staph Trio, Pharmacokinetics of Antistaphylococcal Antibiotics in Infants; CLIN01, Safety and Pharmacokinetics of Multiple-Dose Intravenous and Oral Clindamycin in Pediatric Subjects with BMI ≥ 85th Percentile; Prop., proportional residual error.